Abstract:ObjectiveTo systematically evaluate the efficacy of Xuebijing Injection in the treatment of sepsis complicated with acute kidney injury(AKI), in order to provide a evidence-based reference for the treatment of this disease. Methods PubMed, Cochrane Library, Medline, CNKI, Wanfang Database, and VIP Database were used to search and collect randomized controlled trials(RCTs) of Xuebijing Injection in the treatment of sepsis complicated with AKI. The search was conducted until April 20, 2023. Meta-analysis was performed using RevMan 5.3 software, with analysis subjects including serum creatinine (Scr), tumor necrosis factor (TNF)-α and interleukin (IL)-6 levels, as well as APACHEⅡ score and 28-day mortality. The funnel diagram was used to analyze the publication bias of various studies. Results A total of 21 articles including 1 781 patients were included. Meta-analysis showed that compared with the control group, Xuebijing Injection helped improvement in patient's Scr （SMD=-1.01，95%CI：-1.41 to -0.60, P<0.01）, decrease in TNF- α （SMD=-2.61，95%CI：-3.58 to -1.64, P<0.01）, decrease in IL-6 （SMD=-1.65，95%CI：-2.18 to -1.12, P<0.01）, decrease in APACHE Ⅱ score（SMD=-2.41，95%CI：-3.42 to -1.40, P<0.01）, and decrease in 28-day mortality (RR=0.81, 95%CI: 0.68 to 0.96, P<0.01). Conclusion Xuebijing Injection has good effects of anti-inflammatory and renal function improvement, and its combination with conventional treatment can improve the efficacy of sepsis complicated with AKI.